Sana Biotechnology (SANA) Income from Continuing Operations (2020 - 2026)
Sana Biotechnology (SANA) posted Income from Continuing Operations of 162416000.0 for Q1 2026, down 165.42% sequentially from 61193000.0 in Q4 2025, and up 25.17% YoY from 129761206.43 in Q1 2025.
Powered by 
Analysis
Sana Biotechnology (SANA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Income from Continuing Operations for 7 years, with the latest figure at 162416000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 25.17% year-over-year to 162416000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 534943000.0 (up 16.4% YoY) and the FY2025 annual result came in at 369637000.0, down 5.54% from the prior year.
- Income from Continuing Operations retreated to 162416000.0 in Q1 2026 per SANA's latest filing, from 61193000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 52381000.0 in Q4 2024 and troughed at 493136000.0 in Q4 2023.
- A 5-year average of 193890058.82 and a median of 196659000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 773.18% in 2022, then jumped 89.38% in 2024.
- Over 5 years, Income from Continuing Operations stood at 83412000.0 in 2022, then plunged by 491.21% to 493136000.0 in 2023, then surged by 89.38% to 52381000.0 in 2024, then slipped by 16.82% to 61193000.0 in 2025, then sank by 165.42% to 162416000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 162416000.0, 61193000.0, and 86080000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sana Biotechnology | 1.14 Bn | 1.14 Bn | - | -64.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -64.29 Mn |
| Mar 31, 2026 | -47.66 Mn |
| Dec 31, 2025 | -59.92 Mn |
| Sep 30, 2025 | -42.51 Mn |
| Jun 30, 2025 | -94.40 Mn |
| Mar 31, 2025 | -49.64 Mn |
| Dec 31, 2024 | -49.21 Mn |
| Sep 30, 2024 | -59.18 Mn |
| Jun 30, 2024 | -46.17 Mn |
| Mar 31, 2024 | -107.69 Mn |
| Dec 31, 2023 | -87.89 Mn |
| Sep 30, 2023 | 681,000.00 |
| Jun 30, 2023 | -113.92 Mn |
| Mar 31, 2023 | -81.86 Mn |
| Dec 31, 2022 | -72.98 Mn |
| Sep 30, 2022 | -85.01 Mn |
| Jun 30, 2022 | -74.08 Mn |
| Mar 31, 2022 | -35.49 Mn |
| Dec 31, 2021 | -113.08 Mn |
| Sep 30, 2021 | -83.27 Mn |